Skip to main content

Table 1 Characteristics of patients with advanced NSCLC receiving first-line therapy at Frankfurt University Hospital pre-ICI and post-ICI

From: Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012–2018

Characteristic, n (%)

Overall

(N = 332)

Pre-ICI

Post-ICI

All histologies

(n = 168)

NSQ/other

(n = 136)

SQ

(n = 32)

All histologies

(n = 164)

NSQ/other

(n = 126)

SQ

(n = 38)

Age, yearsa

Median (Q1–Q3)

Min–Max

64 (57–71)

25–86

63 (56–70)

25–86

62 (55–67)

25–86

64 (62–73)

37–82

65 (57–71)

41–86

64.5 (57–71)

41–86

66.5 (60–73)

47–85

Sex, n (%)

Male

190 (57.2)

97 (57.7)

75 (55.1)

22 (68.8)

93 (56.7)

68 (54.0)

25 (65.8)

Smoking status, n (%)b

Ex-smoker

Never smoked

Smoker

Missing/Unknown

113 (34.0)

15 (4.5)

133 (40.1)

71 (21.4)

50 (29.8)

9 (5.4)

63 (37.5)

46 (27.4)

39 (28.7)

9 (6.6)

47 (34.6)

41 (30.1)

11 (34.4)

0

16 (50.0)

5 (15.6)

63 (38.4)

6 (3.7)

70 (42.7)

25 (15.2)

46 (36.5)

6 (4.8)

54 (42.9)

20 (15.9)

17 (44.7)

0

16 (42.1)

5 (13.2)

ECOG PS, n (%)c

0–1

≥ 2

Missing/Unknown

270 (81.3)

57 (17.2)

5 (1.5)

140 (83.3)

26 (15.5)

< 5

112 (82.4)

22 (16.2)

< 5

28 (87.5)

< 5

0

130 (79.3)

31 (18.9)

< 5

102 (81.0)

21 (16.7)

< 5

28 (73.7)

10 (26.3)

0

TNM stage, n (%)b

IA–IIIA

IIIB–IVB

20 (6.0)

312 (94.0)

6 (3.6)

162 (96.4)

5 (3.7)

131 (96.3)

< 5

31 (96.9)

14 (8.5)

150 (91.5)

10 (7.9)

116 (92.1)

< 5

34 (89.5)

Histology, n (%)b

NSQ

SQ

NOS

Other

237 (71.4)

70 (21.1)

< 5

23 (6.9)

124 (73.8)

32 (19.0)

< 5

11 (6.5)

124 (91.2)

0

< 5

11 (8.1)

0

32 (100)

0

0

113 (68.9)

38 (23.2)

< 5

12 (7.3)

113 (89.7)

0

< 5

12 (9.5)

0

38 (100)

0

0

No. of metastatic organ sitesa

Median (Q1–Q3)

1 (1–2)

1 (1–2)

1 (1–2)

1 (0–1)

1 (1–2)

1 (1–2)

1 (0–2)

Brain metastases, n (%)a

Yes

99 (29.8)

50 (29.8)

47 (34.6)

< 5

49 (29.9)

40 (31.7)

9 (23.7)

Liver metastases, n (%)a

Yes

52 (15.7)

27 (16.1)

24 (17.6)

< 5

25 (15.2)

20 (15.9)

5 (13.2)

Bone metastases, n (%)a

Yes

113 (34.0)

51 (30.4)

44 (32.4)

7 (21.9)

62 (37.8)

53 (42.1)

9 (23.7)

PD-L1 testing, n (%)

Not tested

Positive

 ≥ 50%

 1–49%

 Unknown PD-L1 level

Negative (< 1%)

202 (60.8)

89 (26.8)

42 (12.7)

42 (12.7)

5 (1.5)

41 (12.3)

160 (95.2)

7 (4.2)

5 (3.0)

0

< 5

< 5

128 (94.1)

7 (5.1)

5 (3.7)

0

< 5

< 5

32 (100)

0

0

0

0

0

42 (25.6)

82 (50.0)

37 (22.6)

42 (25.6)

< 5

40 (24.4)

24 (19.0)

69 (54.8)

30 (23.8)

37 (29.4)

< 5

33 (26.2)

18 (47.4)

13 (34.2)

7 (18.4)

5 (13.2)

< 5

7 (18.4)

  1. Data were masked when patient numbers for an individual category were greater than zero but less than five.
  2. a At start of first-line therapy
  3. b At diagnosis
  4. c At closest date to start of first-line therapy
  5. ECOG PS Eastern Cooperative Oncology Group performance status, NOS Not otherwise specified, NSQ Non-squamous cell, PD-L1 Programmed death ligand 1, SQ Squamous cell, TNM Tumor node metastasis
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us